597 related articles for article (PubMed ID: 35490371)
21. Mitochondrial Dysfunction in Metabolic Dysfunction Fatty Liver Disease (MAFLD).
Zhao Y; Zhou Y; Wang D; Huang Z; Xiao X; Zheng Q; Li S; Long D; Feng L
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139341
[TBL] [Abstract][Full Text] [Related]
22. [ER stress and NAFLD].
Lachkar F; Papaioannou A; Ferré P; Foufelle F
Biol Aujourdhui; 2020; 214(1-2):15-23. PubMed ID: 32773026
[TBL] [Abstract][Full Text] [Related]
23. Endoplasmic reticulum stress in innate immune cells - a significant contribution to non-alcoholic fatty liver disease.
Zhou L; Shen H; Li X; Wang H
Front Immunol; 2022; 13():951406. PubMed ID: 35958574
[TBL] [Abstract][Full Text] [Related]
24. NAFLD: Mechanisms, Treatments, and Biomarkers.
Nassir F
Biomolecules; 2022 Jun; 12(6):. PubMed ID: 35740949
[TBL] [Abstract][Full Text] [Related]
25. Recent updates on targeting the molecular mediators of NAFLD.
Wang J; Wang L; Zhang XJ; Zhang P; Cai J; She ZG; Li H
J Mol Med (Berl); 2023 Feb; 101(1-2):101-124. PubMed ID: 36792729
[TBL] [Abstract][Full Text] [Related]
26. Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans.
Pafili K; Roden M
Mol Metab; 2021 Aug; 50():101122. PubMed ID: 33220492
[TBL] [Abstract][Full Text] [Related]
27. Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease.
Brown E; Hydes T; Hamid A; Cuthbertson DJ
Clin Ther; 2021 Sep; 43(9):1476-1504. PubMed ID: 34446271
[TBL] [Abstract][Full Text] [Related]
28. Pathophysiological communication between hepatocytes and non-parenchymal cells in liver injury from NAFLD to liver fibrosis.
Kumar S; Duan Q; Wu R; Harris EN; Su Q
Adv Drug Deliv Rev; 2021 Sep; 176():113869. PubMed ID: 34280515
[TBL] [Abstract][Full Text] [Related]
29. Endothelial Cell Dysfunction and Nonalcoholic Fatty Liver Disease (NAFLD): A Concise Review.
Nasiri-Ansari N; Androutsakos T; Flessa CM; Kyrou I; Siasos G; Randeva HS; Kassi E; Papavassiliou AG
Cells; 2022 Aug; 11(16):. PubMed ID: 36010588
[TBL] [Abstract][Full Text] [Related]
30. How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease?
Geng Y; Faber KN; de Meijer VE; Blokzijl H; Moshage H
Hepatol Int; 2021 Feb; 15(1):21-35. PubMed ID: 33548031
[TBL] [Abstract][Full Text] [Related]
31. Understanding the Role of Perilipin 5 in Non-Alcoholic Fatty Liver Disease and Its Role in Hepatocellular Carcinoma: A Review of Novel Insights.
Mass Sanchez PB; Krizanac M; Weiskirchen R; Asimakopoulos A
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34067931
[TBL] [Abstract][Full Text] [Related]
32. Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?
Asrih M; Jornayvaz FR
Mol Cell Endocrinol; 2015 Dec; 418 Pt 1():55-65. PubMed ID: 25724480
[TBL] [Abstract][Full Text] [Related]
33. Silencing of STE20-type kinase TAOK1 confers protection against hepatocellular lipotoxicity through metabolic rewiring.
Xia Y; Andersson E; Anand SK; Cansby E; Caputo M; Kumari S; Porosk R; Kilk K; Nair S; Marschall HU; Blüher M; Mahlapuu M
Hepatol Commun; 2023 Apr; 7(4):. PubMed ID: 36930872
[TBL] [Abstract][Full Text] [Related]
34. Oxidative Stress in NAFLD: Role of Nutrients and Food Contaminants.
Rives C; Fougerat A; Ellero-Simatos S; Loiseau N; Guillou H; Gamet-Payrastre L; Wahli W
Biomolecules; 2020 Dec; 10(12):. PubMed ID: 33371482
[TBL] [Abstract][Full Text] [Related]
35. The specialized proresolving lipid mediator maresin 1 protects hepatocytes from lipotoxic and hypoxia-induced endoplasmic reticulum stress.
Rius B; Duran-Güell M; Flores-Costa R; López-Vicario C; Lopategi A; Alcaraz-Quiles J; Casulleras M; Lozano JJ; Titos E; Clària J
FASEB J; 2017 Dec; 31(12):5384-5398. PubMed ID: 28768719
[TBL] [Abstract][Full Text] [Related]
36. Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease.
Arab JP; Arrese M; Trauner M
Annu Rev Pathol; 2018 Jan; 13():321-350. PubMed ID: 29414249
[TBL] [Abstract][Full Text] [Related]
37. Role of endoplasmic reticulum stress in the pathogenesis of nonalcoholic fatty liver disease.
Zhang XQ; Xu CF; Yu CH; Chen WX; Li YM
World J Gastroenterol; 2014 Feb; 20(7):1768-76. PubMed ID: 24587654
[TBL] [Abstract][Full Text] [Related]
38. The unfolded protein response and hepatic lipid metabolism in non alcoholic fatty liver disease.
Song MJ; Malhi H
Pharmacol Ther; 2019 Nov; 203():107401. PubMed ID: 31419516
[TBL] [Abstract][Full Text] [Related]
39. Endoplasmic Reticulum Stress Related Molecular Mechanisms in Nonalcoholic Fatty Liver Disease (NAFLD).
Wang L; Chen J; Ning C; Lei D; Ren J
Curr Drug Targets; 2018; 19(9):1087-1094. PubMed ID: 29766802
[TBL] [Abstract][Full Text] [Related]
40. Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease: from pig model to human study.
Nakamura N; Hatano E; Iguchi K; Sato M; Kawaguchi H; Ohtsu I; Sakurai T; Aizawa N; Iijima H; Nishiguchi S; Tomono T; Okuda Y; Wada S; Seo S; Taura K; Uemoto S; Ikegawa M
BMC Cancer; 2019 Jun; 19(1):621. PubMed ID: 31238892
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
